Migraine readout completes December hat trick for surging Axsome

Axsome’s winning streak continued as its third auspicious clinical readout this month augurs a planned 2H20 NDA submission that could allow the company to carve out a niche for AXS-07 in acute migraine.

Axsome Therapeutics Inc. (NASDAQ:AXSM) said Monday that its meloxicam/rizatriptan combination significantly beat placebo on the co-primary endpoints of

Read the full 502 word article

How to gain access

Continue reading with a
two-week free trial.